Independent Radiopharmacy Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.
Department of Dermatology, Venerology and Pediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland.
Int J Mol Sci. 2022 May 29;23(11):6084. doi: 10.3390/ijms23116084.
Malignant melanoma (MM) is the most lethal skin cancer. Despite a 4% reduction in mortality over the past few years, an increasing number of new diagnosed cases appear each year. Long-term therapy and the development of resistance to the drugs used drive the search for more and more new agents with anti-melanoma activity. This review focuses on the most recent synthesized anti-melanoma agents from 2020-2022. For selected agents, apart from the analysis of biological activity, the structure-activity relationship (SAR) is also discussed. To the best of our knowledge, the following literature review delivers the latest achievements in the field of new anti-melanoma agents.
恶性黑素瘤（MM）是最致命的皮肤癌。尽管在过去几年中死亡率降低了 4%，但每年新诊断出的病例数量却在不断增加。长期的治疗和对所用药物的耐药性的发展促使人们不断寻找更多具有抗黑色素瘤活性的新药物。本综述重点介绍了 2020 年至 2022 年合成的最新抗黑色素瘤药物。对于选定的药物，除了分析生物活性外，还讨论了结构-活性关系（SAR）。据我们所知，以下文献综述提供了新的抗黑色素瘤药物领域的最新成果。
Zotero 插件
